Arbor Biotechnologies

History

YearDetail
2016 Arbor was founded by Feng Zhang, David Walt, David Scott, and Winston Yan in Massachusetts, U.S.
2017 The company has raised $15.6M in Series A funding.
2018 Discovered Cas13d, a compact RNA-targeting CRISPR nuclease, executed Vertex research collaboration and license agreement and discovered additional subtypes of type V CRISPR-Cas systems.
2019 Optimized first therapeutic candidate for mammalian activity and Discovered type V CRISPR-associated transposase system.
2020 Multiple nuclease candidates demonstrate mammalian activity and Engineering efforts yield candidates with Cas9 equivalent activity.
2021 Expanded partnership with Vertex to include ex vivo engineered cell therapies, Closed $215 Million oversubscribed Series B Financing, and Entered into gene-editing technology licensing deal with Lonza.
2022 Entered license agreement with Edigene to advance ex vivo engineered cell therapy programs, Established a Engineered Cas12i2 as platform for genome editing.
2023 Expanded strategic partnership with Vertex to include RT editing and Established partnership with Ginkgo Bioworks to accelerate RT editor screening/optimization.
AI Sentiment